News

A treatment for myasthenia gravis, a rare muscle wasting condition ... shortness of breath and weakness in the neck, arms and legs. Symptoms usually start in women under 40 and men over 60, but the ...
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND ...
Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset ... Immunosuppressive drug treatment should be actively undertaken until all major symptoms are in a stable remission.
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
SCOTTSDALE, Ariz. — June 16, 2025 — The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those ...
Andy Stephenson says the drug led to improvements in his symptoms, but many cannot to afford use it. Skip to content. ... Myasthenia gravis causes fatigue and muscle weakness, double vision, ...
Three models were fitted to examine factors associated with depressive symptoms: (a) all men (n = 1,907); (b) non-Hispanic Black men only (n = 1,117); and (c) Hispanic men only (n = 790). Model ...
Background Myasthenia Gravis (MG) is an autoimmune disorder presenting with fatigable muscle weakness leading to potential respiratory distress. Clinical management aims to improve patient quality of ...
The Food and Drug Administration (FDA) has approved Imaavy ™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older ...
Myasthenia gravis affects both men and women and occurs across all races and ethnicities. Its incidence and prevalence are higher in women under age 50 and in men ages 65 and older.
People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...